NCT03421314 is a NA clinical trial of Zinc gluconate and/or Selenium yeast in HIV, sponsored by Instituto Nacional de Enfermedades Respiratorias.

Who is sponsoring NCT03421314?

NCT03421314 is sponsored by Instituto Nacional de Enfermedades Respiratorias.

What drugs are being tested in NCT03421314?

Interventions in NCT03421314: Zinc gluconate and/or Selenium yeast.

What condition does NCT03421314 study?

NCT03421314 studies HIV, ART, Zinc Deficiency, Selenium Deficiency, Metabolic Complication, Inflammation.

Is NCT03421314 still recruiting?

NCT03421314 is currently status unknown. Last updated 30 January 2019.

Last reviewed 2019-01-30 · How we verify

NCT03421314

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Zinc and Selenium Supplementation on HIV+ Individuals on Antiretroviral Treatment.

Status unknown NA Last updated 30 January 2019

What this trial tests

NA trial testing Zinc gluconate and/or Selenium yeast in HIV in 37 participants. Status unknown.

Timeline

1 September 2016

Primary endpoint
31 December 2019

1 January 2020

Quick facts

Lead sponsor	Instituto Nacional de Enfermedades Respiratorias
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	supportive care
Enrollment	37
Start date	1 September 2016
Primary completion	31 December 2019
Estimated completion	1 January 2020
Sites	1 location across Mexico

Drugs / interventions tested

Zinc gluconate and/or Selenium yeast

Conditions studied

HIV — all drugs for HIV →
ART — all drugs for ART →
Zinc Deficiency — all drugs for Zinc Deficiency →
Selenium Deficiency — all drugs for Selenium Deficiency →

Sponsor

Instituto Nacional de Enfermedades Respiratorias — full company profile →

Who can join

Adults 18 to 65, male only, with HIV or ART. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the effect of zinc gluconate and/or selenium yeast supplementation during six months on clinical (glucose, cholesterol, triglycerides, bone mineral density and body composition) and immunological (oxidative stress, CD4+ count and pro-inflammatory cytokines) parameters in a population with HIV diagnosis on antiretroviral treatment.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Zinc and selenium supplementation on treated HIV-infected individuals induces changes in body composition and on the expression of genes responsible of naïve CD8+ T cells function.
Osuna-Padilla IA, Rodríguez-Moguel NC, Aguilar-Vargas A, Tolentino-Dolores M, et al · · 2024 · cited 2× · PMID 39351495 · DOI 10.3389/fnut.2024.1417975

Verify or expand the search:

Other recruiting trials for HIV

Currently open trials in the same condition.

NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT07221214 — GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · recruiting
NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV · NA · recruiting
NCT07390474 — Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA i · Phase 1 · recruiting
NCT07390955 — A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 · Phase 1 · recruiting

Other Instituto Nacional de Enfermedades Respiratorias trials

Trials by the same sponsor.

NCT06471101 — Applying Artificial Intelligence to Identify Subphenotypes of Acute Kidney Injury in Mexican Patients With Severe COVID- · completed
NCT06691321 — Caspofungin for Pneumocystis Pneumonia in PLWHIV. · recruiting
NCT04443673 — Glycine Supplement for Severe COVID-19 · NA · terminated
NCT04517630 — Renal Biomarkers in AKI and COVID-19 · completed
NCT06444893 — Morphofunctional, Gene, Inflammation Molecules and Oxidative Stress Analysis in Kidney Tissue of COVID-19 Patients · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03421314 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Instituto Nacional de Enfermedades Respiratorias
Last refreshed: 30 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03421314.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing